A positive antimitochondrial antibody M2 subtype suggests the possibility of primary biliary cirrhosis (PBC), the severity of which depends on the patient’s general status and the presence of comorbidities.
Anti-mitochondrial antibody M2 subtype (AMA-M2) positivity can be seen early in the course of PBC, and has a high sensitivity and specificity. The prognosis of PBC is generally poorer if it is combined with other diseases, such as autoimmune hepatitis (AIH) and non-alcoholic steatohepatitis.
In addition, patients with PBC need to undergo regular alpha-fetoprotein and imaging tests after entering the cirrhotic stage, and the prognosis will be affected by the occurrence of primary hepatocellular carcinoma.
Primary biliary cirrhosis (PBC) is an autoimmune chronic inflammatory disease of the liver, with pathologic manifestations of chronic inflammation of the non-purulent intrahepatic bile ducts and lymphocytic infiltration of the confluent area, which may be related to autoimmunity, infection, and cytopathy.
PBC is mainly treated with ursodeoxycholic acid, in addition to modulating immunotherapy, antifibrotic therapy and liver transplantation.
Overall, positive anti-mitochondrial antibody M2 type suggests the possibility of PBC, which requires further examination in the hospital and early, standardized treatment.